Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014

TEL-AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and...
April 30, 2014 11:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Results for the First Quarter of 2014

Key financial highlights include: A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...
April 30, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014

RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers In light of the positive results, and subject to regulatory...
April 29, 2014 10:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014

TEL-AVIV, Israel, April 29, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
April 28, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014

TEL-AVIV, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...
April 24, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film

TEL-AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...
April 07, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application

The Company concluded a positive scientific advice meeting with the UK MHRA regarding RHB-102 and plans to submit, during the second half of the year, a European marketing application for the...
March 07, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 26th Annual ROTH Conference

TEL-AVIV, Israel, March 7, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
March 07, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property

RHB-102 is a proprietary once-daily oral antiemetic RedHill has secured from Temple University direct rights to the original RHB-102 patents and has terminated its agreement with SCOLR...
March 03, 2014 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

TEL-AVIV, Israel, March 3, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and...